Development and homeostasis of the cardiovascular system require intimate interactions between endothelial and smooth muscle cells, which form a seamless circulatory network. We show that histone deacetylase 7 (HDAC7) is specifically expressed in the vascular endothelium during early embryogenesis, where it maintains vascular integrity by repressing the expression of matrix metalloproteinase (MMP) 10, a secreted endoproteinase that degrades the extracellular matrix. Disruption of the HDAC7 gene in mice results in embryonic lethality due to a failure in endothelial cell-cell adhesion and consequent dilatation and rupture of blood vessels. HDAC7 represses MMP10 gene transcription by associating with myocyte enhancer factor-2 (MEF2), a direct activator of MMP10 transcription and essential regulator of blood vessel development. These findings reveal an unexpected and specific role for HDAC7 in the maintenance of vascular integrity and have important implications for understanding the processes of angiogenesis and vascular remodeling during cardiovascular development and disease.
INTRODUCTION
Changes in histone acetylation alter chromatin structure and serve as a key mechanism for the control of gene expression (Jenuwein and Allis, 2001) . Histone acetyltransferases (HATs) stimulate transcription by acetylating nucleosomal histones, which relaxes chromatin structure and facilitates recruitment of transcription factors to DNA target sequences. The stimulatory effect of HATs on gene expression is counteracted by histone deacetylases (HDACs), which remove acetyl groups from histones and promote chromatin condensation with consequent transcriptional repression.
Mammalian HDACs can be classified based on their structure and homology to Saccharomyces cerevisiae HDACs (Grozinger and Schreiber, 2002) . Class I HDACs (HDAC1, 2, 3, 8, and 11), which are ubiquitously expressed, are homologous to yeast RPD3. Class II HDACs (HDAC4, 5, 7, and 9) share homology with yeast HDA1 and display tissue-restricted expression patterns. Class II HDACs contain an amino-terminal extension that interacts with other transcriptional cofactors and confers responsiveness to extracellular signals (Verdin et al., 2003) . Phosphorylation of the amino termini of class II HDACs by calcium/calmodulin-dependent kinase (CaMK) and protein kinase D (PKD) creates docking sites for the 14-3-3 family of chaperone proteins, which promote shuttling of these HDACs from the nucleus to the cytoplasm, thereby derepressing HDAC target genes (McKinsey et al., 2000a (McKinsey et al., , 2000b Vega et al., 2004a) .
Class II HDACs appear to be dedicated to the control of tissue growth and development. HDAC5 and HDAC9 act as negative regulators of cardiac growth. Mutant mice lacking either of these HDACs develop extremely enlarged hearts in response to pathological signals (Chang et al., 2004b; Zhang et al., 2002) . Conversely, mutants of HDAC5 and HDAC9 lacking the regulatory phosphorylation sites prevent cardiomyocyte growth. Consistent with these observations, HDAC5 and HDAC9 associate with and repress the activity of myocyte enhancer factor-2 (MEF2), a MADS-box transcription factor involved in muscle growth and development (McKinsey et al., 2000a (McKinsey et al., , 2000b Zhang et al., 2002) .
HDAC4 is expressed in prehypertrophic chondrocytes of the developing skeleton and determines the timing and extent of endochondral bone formation (Vega et al., 2004b) . Mice homozygous for an HDAC4 mutation exhibit lethal ossification of endochondral cartilage due to ectopic hypertrophy of chondrocytes, whereas ectopic expression of HDAC4 in chondrocytes inhibits hypertrophic growth and differentiation.
In the present study, we generated mice lacking HDAC7, the last of the class II HDACs to be analyzed in vivo. Remarkably, HDAC7 null mice die during midgestation from vascular dilatation and rupture caused by loss of adhesion between endothelial cells (ECs). Consistent with this phenotype, HDAC7 is expressed specifically in the developing vascular endothelium, where it represses the expression of matrix metalloproteinase 10 (MMP10), a secreted endoproteinase that degrades the extracellular matrix and perturbs vascular integrity (Saunders et al., 2005) . In HDAC7 mutant embryos, MMP10 expression is dramatically upregulated in the vascular endothelium, and its antagonist, tissue inhibitor of metalloproteinase 1 (TIMP1), is downregulated. HDAC7 represses the promoter of the MMP10 gene by association with MEF2, a direct activator of MMP10 transcription. These findings reveal an unexpected and specific role for HDAC7 in the maintenance of vascular integrity and have important implications for understanding the mechanisms of angiogenesis and vascular remodeling during cardiovascular development and disease.
RESULTS

Generation of HDAC7 Mutant Mice
To explore the functions of HDAC7 in vivo, we inactivated the mouse HDAC7 gene by homologous recombination in embryonic stem (ES) cells and generated HDAC7 mutant mice. The targeted mutation deleted exons 2 to 5, which encode residues 1-130 that encompass the MEF2 binding domain of the protein. The mutation also introduced a promoter-less nuclear b-galactosidase protein coding region inframe with the initiation codon of the HDAC7 gene ( Figure 1A ). Targeting of HDAC7 in ES cells was confirmed by Southern blot analysis ( Figure 1B ).
Mice heterozygous for the HDAC7 mutation were viable, fertile, and phenotypically normal. Heterozygote intercrosses in the isogenic SvEv129 background, as well as in the SvEv129/C57BL6 mixed background, failed to yield any live HDAC7 homozygous mutant pups. By timed matings of heterozygous mutant mice, we determined that the genotypes of embryos showed Mendelian ratios of inheritance up to E11.0, but no viable homozygous mutants were obtained at later developmental time points (Table S1) .
HDAC7 mutant mice were indistinguishable from wildtype embryos before E10.75. However, by E11.0, all HDAC7 mutant embryos displayed widespread vascular rupture, pericardial effusion, and enlarged dorsal aortae, indicative of abnormalities in the circulatory system ( Figure 1C) .
RT-PCR analysis of RNA from HDAC7 mutant embryos at E10.5 revealed that HDAC7 transcripts were absent in homozygous mutants ( Figures 1D and 1E ). Transcripts encoding other HDACs were expressed at normal levels in mutant embryos ( Figure 1F ).
Endothelial Cell-Specific Expression of HDAC7
To begin to determine the cause of lethality in HDAC7 mutant embryos, we analyzed HDAC7 expression by in situ hybridization. HDAC7 transcripts were first detected at E9.5 in ECs within the heart and blood vessels and in mesenchyme (Figure 2Aa ). At E11.0, HDAC7 expression was restricted to ECs lining the vessels and endocardial cells within the cardiac chambers (Figure 2Ab ). At E15.5, expression of HDAC7 was also prominent in the myocardial layer of the heart and in lung tissue (Figure 2Ac ).
Mouse embryos harboring the HDAC7 mutation expressed lacZ in a pattern corresponding to that of the endogenous HDAC7 gene. Cardiovascular specific expression of lacZ was observed at E9.5 (Figure 2Ba ). At E11.0, lacZ was predominantly expressed in large and small vessels, arteries and veins, and the heart. Low expression in neural tube was also observed (Figure 2Bb ). Histologic sections of E11.0 embryos revealed that lacZ expression was restricted to the ECs of the vasculature and endocardial cells of the heart (Figures 2Ca-2Cf) . lacZ expression was not observed in myocardium at this stage. lacZ staining of adult tissues from heterozygous mutant mice showed that HDAC7 was highly expressed in lung, heart, skeletal muscle, and vessels (data not shown), consistent with the pattern of HDAC7 transcripts detected by Northern blot (Kao et al., 2000) . Histological sections showed that lacZ was actually expressed specifically in the ECs of the small vessels and capillaries within these tissues. For instance, the ECs, but not the smooth muscle cells (SMCs), of the ascending aorta strongly expressed lacZ ( Figure 2Da ); in the adult heart, lacZ was highly expressed in the endocardial cells of the ventricles and atria and in the small veins and capillaries amidst the cardiac muscle fibers, but not in cardiomyocytes ( Figures  2Db-2Dd ). High lacZ expression was also observed in capillaries of skeletal muscle and lung, while the skeletal muscle fibers per se and the bronchi and alveoli did not show lacZ staining (Figures 2De-2Df ). HDAC7 expression was undetectable in the yolk sac vasculature (data not shown).
Cardiovascular Abnormalities in HDAC7 Mutant Mice
The dorsal aortae and cardinal veins were severely enlarged and frequently ruptured, and there were fewer than normal SMCs surrounding dorsal aortae in the mutant embryos at E11.0 ( Figure 3A) . The branchial arteries also were grossly enlarged, although not as severely as the dorsal aortae ( Figure 3B ). In mutant embryos, rightward looping and chamber formation were normal, but the myocardial walls of the ventricular chambers were abnormally thin and atria were dilated ( Figure 3A) .
Electron microscopy showed tight junctions between adjacent ECs in dorsal aortae and cardinal veins in wildtype embryos, but such junctions were often missing in mutant embryos prior to death ( Figure 3C ). Instead, ECs appeared to extend processes that failed to establish tight EC-cell interactions, which are essential for maintaining vascular integrity. It was also noticeable that SMCs attached well to ECs of the aorta in wild-type embryos, while there were large intercellular spaces between ECs and surrounding SMCs in the mutant (Figures 3Ca and  3Cb ).
Normal Differentiation and Patterning of Endothelial and SMCs in HDAC7 Mutant Embryos
In light of the specific expression of HDAC7 in embryonic ECs by E11.0 and the obvious morphological abnormalities in this cell population as revealed by electron microscopy, we examined for possible defects in EC differentiation in HDAC7 mutant embryos. A panel of molecular markers important for vasculogenesis, including VEGF, flk1, flt1, tie1, tie2, Flt4, ETA, Erb3, Neuregulin, ARNT, Hif1a, Hrt1, Hrt2, Smad5, LKLF, eNOS, PDGFB, and MEF2C , was analyzed either by RT-PCR or RNA in situ hybridization, but no changes in the expression levels of these genes were observed ( Figure 4A and data not shown). Among these genes, tie1, tie2, Ang-1, and Ang-2 are involved in recruitment of SMCs by ECs (Thurston, 2003) .
To visualize the primitive vasculature plexus, we stained E10.5 embryos with an antibody against PECAM, an ECspecific marker. As shown in Figures 4Ba-4Bh , differentiated ECs were properly positioned in the mutant embryos. The complexity and patterning of the cranial vasculature, the intersomitic vasculature, and the dorsal aortae as revealed by PECAM staining were also similar in wild-type and HDAC7 mutant embryos. Transverse sections showed the presence of ECs in the dorsal aortae and cardinal veins in both wild-type and HDAC7 mutant embryos, although the vessels in the mutant embryos were larger than normal. Similarly, PECAM staining was detected in the endocardium of wild-type and mutant embryos ( Figure 4C ). These results indicated that EC differentiation and patterning were unaffected by disruption of the HDAC7 gene.
Recruitment of SMCs by arterial ECs provides contractility and mechanical support for the developing arteries. To investigate whether the vascular abnormalities in HDAC7 mutant embryos were caused by a defect in recruitment or differentiation of SMCs, we performed whole-mount antibody staining for smooth muscle (SM) aactin. Normal patterning of SMCs was observed in mutant embryos, suggesting that vascular ECs were capable of recruiting SMCs. However, the staining of SM a-actin in the dorsal aorta was less prominent in the mutant than normal (Figures 4Da-4Df ). Immunostaining against Ephrin B, an arterial-specific EC marker, confirmed that SMCs in the dorsal aorta in the mutant embryos correctly adopted the arterial fate (data not shown). However, fewer SM aactin-positive cells were observed in mutant compared to wild-type embryos (arrowheads in Figures 4De-4Df ), suggesting a possible abnormality in recruitment of SMCs by ECs in the absence of HDAC7. TUNEL staining showed no difference in apoptosis in endothelial and SMC populations between wild-type and mutant embryos (data not shown). We conclude that the absence of HDAC7 results in a specific abnormality in EC-cell adhesion and recruitment of SMCs with consequent vascular rupture and embryonic death.
EC-Specific Deletion of HDAC7
To confirm that HDAC7 acted cell autonomously within ECs to control vascular integrity, we generated mice bearing a conditional HDAC7 null allele, referred to as Figure 5A ). The targeting strategy introduced loxP sites in introns 1 and 10, such that Cre-mediated recombination would result in the deletion of residues 1-435 of the N-terminal domain of the protein ( Figure 5B ). ES cell clones heterozygous for the HDAC7 flox mutation were used to generate chimeric mice. Transmission of the conditional allele from male chimeras through the germline was confirmed by PCR analysis ( Figure 5B ). The mutation introduced a neomycin resistance cassette, which was removed in the germline by crossing with FLPe animals ( Figure 5A ). Mice homozygous for the HDAC7 flox allele were phenotypically normal, indicating that the presence of the loxP (Kisanuki et al., 2001 ) resulted in embryonic lethality at E11.5 and cardiovascular abnormalities similar to those of HDAC7 knockout mice ( Figure 5C ). As was observed with the global deletion, the lethal phenotype resulting from endothelialspecific HDAC7 gene deletion was 100% penetrant. Aortic enlargement was more moderate than in the null animals. However, the conditional deletion displayed all of the cardiovascular features seen in the nulls, including a reduction in arterial SMC numbers, endothelial elongation, multifocal hemorrhages, edema, and myocardial thinning. In contrast, HDAC7 flox/KO mice bearing a Cre transgene controlled by the a-myosin heavy chain promoter, which directs expression in cardiomyocytes, were viable (data not shown). We conclude that HDAC7 is required specifically in embryonic ECs for cell-cell adhesion and maintenance of vascular integrity.
Altered Gene Expression by Knockdown of HDAC7 in ECs In Vitro
In an effort to identify potential HDAC7 target genes in ECs that might reveal the mechanism by which HDAC7 controls vascular integrity, we used RNAi to suppress HDAC7 expression in Human Umbilical Vein ECs (HUVECs). In HUVECs transfected with siRNA specific for HDAC7 mRNA, HDAC7 transcripts were downregulated at least 70% compared to controls as confirmed by immunostaining ( Figure 6A ). When cultured on matri-gel, HUVECs spontaneously organize into a primitive vascular network. In the presence of HDAC7 siRNA, HUVECs failed to adhere to each other and instead remained as single cells or clumps of cells (Figure 6Bb ). In contrast, GFP siRNA, as a control, had no effect on the ability of HUVECs to become organized into an endothelial lattice (Figure 6Ba) .
Microarray analysis to compare the gene expression profiles of HUVECs treated with HDAC7 siRNA and controls revealed that numerous genes encoding extracellular matrix and adhesion proteins were dysregulated in the presence of HDAC7 siRNA (Table S2 ). Of particular interest were the genes encoding matrix metalloproteinase 10 (MMP10), also referred to as stromelysin 2, which was upregulated by 6.5-fold, and its inhibitor tissue inhibitor of metalloproteinase 1 (TIMP1), which was downregulated by 8.6-fold. MMP10 is a secreted proteinase that degrades the extracellular matrix, and TIMP1 inhibits MMP10 activity (Rundhaug, 2005; Yoon et al., 2003) . Thus, the upregulation of MMP10 and concomitant downregulation of TIMP1 would be predicted to disrupt cell-cell adhesion and perturb vascular integrity in HDAC7 mutant embryos. The changes in expression of these genes in HUVECs treated with siRNA targeted to HDAC7 were validated by RT-PCR ( Figure 6C ). Consistent with the potential involvement of MMP10 in endothelial abnormalities associated with loss of HDAC7 function, adenoviral-mediated misexpression of MMP10 in cultured HUVECs impaired the angiogenic ability of HUVECs, although the defect was not as dramatic as the effect of HDAC7 RNAi (Figure 6Bd) . Treatment of EC cultures with TIMP1 siRNA caused a similar loss of adhesiveness (Figure 6Bc) . The combined effect of TIMP1 knockdown and MMP10 overexpression was very similar to the effect of HDAC7 knockdown (Figure 6Be ), indicating that it is very likely that MMP10 and TIMP1 are involved in the regulation of vascular integrity by HDAC7. Gene expression changes were confirmed by RT-PCR ( Figure 6C) .
We further examined the expression of MMP10 and TIMP1 in HDAC7 mutant embryos by immunohistochemistry. Consistent with their expression in cultured ECs, MMP10 was dramatically upregulated in the perivascular region, while TIMP1 was downregulated in vascular ECs in mutant embryos ( Figure 6D ). The diffuse staining pattern of these proteins in the perivascular region reflects the fact that they are secreted.
MMP10 Is a Direct Target of MEF2 and HDAC7
Given the fact that HDAC7 is a transcriptional repressor and MMP10 is upregulated in HDAC7 mutant embryos, we searched for evolutionarily conserved sequences in the upstream region of the MMP10 gene that might control expression of MMP10 in ECs. Two AP-1 sites and two PEA3 sites in the MMP10 promoter are responsible for constitutive expression and induction by inflammation (Chakraborti et al., 2003) .
We identified a potential MEF2 site in the MMP10 promoter, and DNA binding assays using extracts from COS cells transfected with a Myc-MEF2C expression plasmid confirmed that this site was a bona fide binding site for MEF2 ( Figure 7A ). The MEF2-consensus sequence from the MMP10 promoter bound MEF2C comparably to the canonical MEF2 site from the muscle creatine kinase (MCK) enhancer (Gossett et al., 1989) (Figure 7B ). This DNA-protein complex was super-shifted by anti-Myc antibody and was abolished in the presence of an excess of the unlabeled cognate DNA sequence or the MCK MEF2 site as a competitor, whereas a mutant sequence failed to compete for MEF2C binding ( Figure 7B) . Similarly, the DNA-protein complex between MEF2 and the MCK MEF2 site was abolished by an excess of unlabeled MCK MEF2 sequence or MMP10 MEF2 sequence but not by the mutant sequence ( Figure 7B) .
A DNA fragment containing the MMP10 MEF2 site conferred MEF2 responsiveness to a luciferase reporter in transfected COS cells, and mutation of the MEF2 site completely abolished responsiveness to MEF2 (Figure 7C) . Moreover, HDAC7 prevented activation of the MMP10 promoter by MEF2. A mutant of HDAC7 lacking the MEF2 binding domain (HDAC7-DMEF) failed to inhibit the MMP10 promoter, whereas a mutant lacking the signal-responsive serines (HDAC7-S/A), which functions as a ''super-repressor, '' showed greater repressive activity against MEF2 ( Figure 7D ). To further validate the association of MEF2C with the MMP10 promoter, we performed chromatin immunoprecipitation (ChIP) assays. As shown in Figure 7E , MEF2, which is expressed in and required for EC differentiation (Lin et al., 1997 (Lin et al., , 1998 , was detected on the MMP10 promoter in the context of native chromatin in Human Aortic ECs (HAECs). In addition, endogenous HDAC7 and the HATs CBP and p300 were detected on the MMP10 promoter, which suggests that the balance of HDAC and HAT activity at the promoter plays a critical role in controlling the expression of MMP10. We conclude that MEF2 binds directly to the regulatory region responsible for expression of MMP10 in ECs and that HDAC7 and HATs are recruited by MEF2 to the MMP10 gene where they regulate MMP10 expression antagonistically.
To further explore the potential influence of histone acetylation/deacetylation on MMP10 expression, we infected HAEC cultures with an adenovirus encoding a signal-resistant HDAC5 mutant, which, like HDAC7, represses MEF2 activity (McKinsey et al., 2000a) . As shown in Figure 7F , cultures infected with Ad-Flag-HDAC5 showed a reduction in expression of MMP10 expression, as detected by RT-PCR. Association of Flag-HDAC5 with the MMP10 promoter was confirmed by ChIP assay and was accompanied by a decrease in acetylated histone H3 on the promoter detected by ChIP assay with Acetyl-H3 antibody. In contrast, we detected no change in acetylation of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene, which is not regulated by class II HDACs. These findings support the conclusion that recruitment of HDAC7 to the MMP10 promoter by MEF2 represses MMP10 expression, whereas loss of HDAC7 activates MMP10 expression.
DISCUSSION
The results of this study reveal a key role of HDAC7 in maintenance of vascular integrity. Disruption of the HDAC7 gene, which is expressed specifically in ECs, results in embryonic lethality by E11.0 due to cardiovascular defects that include dilated and ruptured blood vessels, dilated atria, and thin-walled myocardium. ECs of HDAC7 mutant embryos appear normal during initial differentiation and patterning but display cell-cell adhesion defects accompanied by upregulation of MMP10. Promoter analysis revealed that MMP10 is a direct target of MEF2, a key transcription factor required for EC differentiation, suggesting that HDAC7 regulates vascular permeability, at least in part by modulating MMP10 expression through inhibiting MEF2 activity, as schematized in Figure 7G .
Regulation of Vascular Integrity by HDAC7
Formation of the vasculature involves two sequential steps: vasculogenesis, the initial formation of a primary vascular plexus, and angiogenesis, a process of sprouting or splitting of blood vessels and remodeling of vascular beds (Cleaver and Krieg, 1999) . During both processes, ECs recruit supporting cells, SMCs in major arteries, and pericytes in microvessels to provide contractility and mechanical support.
The primary defect in HDAC7 mutant embryos is the loss of vascular integrity with consequent embryonic demise. Formation of the primary vascular plexus-vasculogenesis, which begins at E7.5 in mice-is unperturbed in HDAC7 mutant embryos. At E9.5, when HDAC7 expression is first detectable in the vascular endothelium, recruitment of the first layer of SMCs is essentially complete, which explains why perivascular SM a-actin staining is detected in HDAC7 mutant embryos. However, by E11.0, the ability of ECs in HDAC7 mutant embryos to recruit supporting cells appears to be compromised, as evidenced by perivascular hypocellularity in the mutants and associated loss of EC-cell adhesion. We postulate that the onset of vascular disruption in HDAC7 mutant embryos reflects the dissolution of EC-cell interactions, as the weakened vessel wall can no longer withstand the increasing hemodynamic pressure from the ever-increasing activity of the heart. The finding that EC-specific deletion of HDAC7 results in the same phenotype as global deletion of the gene confirms the specific requirement of HDAC7 in the developing vascular endothelium.
Vascular integrity is maintained by tight junctions between adjacent ECs, which form the seamless inner lining of blood vessels. During angiogenesis, MMPs degrade components of the extracellular matrix including the junctional complex, which facilitates detachment of supporting cells and permits ECs to migrate into surrounding tissues (Rundhaug, 2005; Yoon et al., 2003) . MMP10 has been shown to activate other MMPs, such as MMP1, with consequent acceleration of capillary tube regression of ECs in vitro (Saunders et al., 2005) . TIMPs, which (C) Responsiveness of MMP10 gene promoter to MEF2. COS-1 cells were transfected with pGL3-Luc reporter containing the region from À886 bp to +11 bp of the MMP10 gene with indicated amounts of MEF2D. Mutation of the predicted MEF2 site completely abolished the responsiveness of the MMP10 promoter to MEF2D. Values represent the mean ± standard deviation (SD). (D) Activation of MMP10 promoter by MEF2 is inhibited by wild-type HDAC7 and signal-resistant HDAC7 mutant (HDAC7-S/A) but not by an HDAC7 mutant lacking the MEF2 binding domain (HDAC7-DMEF). Values represent the mean ± standard deviation (SD). (E) ChIP assays were performed with chromatin prepared from HAECs. Chromatin was immunoprecipitated with mouse IgG or antibodies against acetylated histone H3, MEF2, HDAC7, CBP, or p300, and precipitated genomic DNA was analyzed by PCR using primers for the MMP10 promoter, which contains an MEF2 binding site. PCR amplification was performed prior to immunoprecipitation for the input control. (F) HAECs were infected with adenovirus encoding either GFP or a constitutively nuclear form of HDAC tagged with Flag epitope. ChIP and RT-PCR analysis were performed 48 hr after infection. HDAC was detected on the MMP10 promoter region, which resulted in hypo-acetylation of the promoter, and consequently MMP10 mRNA expression was reduced when HDAC was overexpressed. In contrast, there was no change in histone acetylation at the GAPDH promoter in response to HDAC overexpression, demonstrating the specificity of this response for MMP10. (G) A model for modulation of MMPs by HDAC7 through inhibition of MEF2 activity. MMP10 expression is controlled by MEF2, which is antagonized by HDAC7 in ECs. In the absence of HDAC7, MMP10 is overexpressed. Combined with downregulation of TIMP1, the extracellular matrix is greatly disrupted, which leads to dilatation and rupture of blood vessels. represent a family of endogenous MMP inhibitors, are highly expressed in ECs and provide native protection from breakdown of the endothelium (Handsley and Edwards, 2005) . The upregulation of MMP10 was accompanied by downregulation of its inhibitor TIMP1, which would be expected to further exacerbate the abnormalities in vascular integrity.
Regulation of MMP10 by MEF2 and HDAC7 during Endothelial Development MEF2C is highly expressed in the developing vascular endothelium, and MEF2C knockout mice die at E9.5 from vascular abnormalities that have been attributed in part to endothelial defects (Lin et al., 1997 (Lin et al., , 1998 . MEF2 serves as a platform for the mutually exclusive recruitment of class II HDACs or p300 . Class II HDACs, including HDAC7, contain a short peptide sequence near their N termini that tethers them to MEF2, resulting in repression of MEF2 target genes such as MMP10. Signaling pathways involving G protein-coupled receptors and calcium-dependent protein kinases lead to the phosphorylation of serine residues in the N-terminal regulatory domains of class II HDACs (Chang et al., 2005; Dressel, et al., 2001; McKinsey et al., 2000a McKinsey et al., , 2000b Vega et al., 2004a) . When phosphorylated, these sites bind 14-3-3 chaperone proteins, which escort class II HDACs from the nucleus to the cytoplasm, freeing MEF2 from the repressive influence of class II HDACs (McKinsey et al., 2000b) and allowing p300 to dock on MEF2 and stimulate MEF2-dependent transcription. Our results show that HDAC7 potently represses the MMP10 promoter, whereas a mutant form of HDAC7 lacking the MEF2 binding domain is unable to repress MMP10 transcription. By ChIP assays, we detected HDAC7 and p300/CBP on the MMP10 promoter, suggesting that the activity of the promoter is dependent on a balance between the positive and negative influences of these MEF2 cofactors, respectively. Class I HDACs have also been implicated in the regulation of extracellular matrix proteins including MMPs through unknown mechanisms (Whetstine et al., 2005) , and HDAC inhibitors regulate MMP activity by inducing the expression of RECK, a repressor of MMPs (Ailenberg and Silverman, 2002; Chang et al., 2004a; Liu et al., 2003b) .
Implications
The realization that HDAC7 regulates MMP10 expression and vascular integrity has potentially important implications for a variety of human disorders. Vascular leakage causes circulatory collapse and contributes to the pathogenesis of numerous, usually life-threatening diseases such as atherosclerosis and aneurysms. The balance between MMP and TIMP activity is critical for maintaining the integrity of the cardiovascular system. The upregulation of MMP10 and concomitant downregulation of TIMP1 expression observed in HDAC7 mutant embryos is reminiscent of the change in expression of these two families of antagonistic proteins in multiple cardiovascular disorders.
Following myocardial infarction, for example, MMP9 expression is upregulated, while TIMP1 expression is downregulated (Cleutjens and Creemers, 2002; Creemers et al., 2001) . Heart failure and ventricular dilatation is associated with similar changes in expression of MMPs and TIMPs (Spinale, 2002) . The imbalance between these opposing proteins has been implicated in pathological remodeling of the myocardium and has pointed to the potential usefulness of MMP inhibitors in restoration of cardiac function in these disorders (Creemers et al., 2003) . The mechanisms responsible for the dysregulation of MMP and TIMP expression in these disorders have not been defined. MMP10 and TIMP1 have been shown to be associated with aortic aneurysm, characterized by destructive remodeling of the vascular extracellular matrix and rupture of the vessel wall, and are likely to contribute to disease pathogenesis (Ogata et al., 2005a) . Thus, strategies to suppress MMP10 expression and maintain TIMP expression by maintaining HDAC7 activity would be predicted to have therapeutic value.
Tumor angiogenesis is also an essential step in metastasis that requires formation of a stable endothelial plexus. MMP inhibitors as well as HDAC inhibitors have been used to prevent metastasis and treat cancer (Ailenberg and Silverman, 2002; Kim et al., 2000; Liu et al., 2003a Liu et al., , 2003b London et al., 2003; Ogata et al., 2005b) . We predict that inhibition of HDAC7 activity in tumors and consequent upregulation of MMPs would also have antiangiogenic consequences and eventually lead to regression of tumors due to the disruption of vascular supply. Hence, these findings point to HDAC7 as a potential therapeutic target for vascular-related disorders including heart failure, aortic aneurysm, and tumorigenesis.
EXPERIMENTAL PROCEDURES
Generation of HDAC7 Mutant Mice
Both HDAC7 KO and HDAC7 loxP alleles were generated by homologous recombination in ES cells. Targeted ES cells carrying each disrupted allele were injected to E3.5 C57BL/6 mouse blastocysts to produce chimeric mice. Chimeras were mated with C57BL/6 females to obtain F1 mice carrying the targeted allele. For detailed procedures, please see Supplemental Data.
RNA In Situ Hybridization and Histology
Embryos and tissues used for histology were fixed in 4% paraformaldehyde, sectioned, and processed for hematoxylin and eosin (H&E) staining or in situ hybridization by using standard procedures (Shelton et al., 2000) . 35 S-labeled RNA probes were generated using Maxiscript kit (Amersham). Signals were pseudocolored in red using Adobe Photoshop.
RT-PCR and Microarray Analysis
Total RNA was extracted from embryos or HUVECs using Trizol reagent (Invitrogen) and used as a template for reverse transcriptase with random hexamer primers (Invitrogen). Primer sequences for specific genes are available upon request. Microarray analysis was performed using Human Genome U133 Plus 2.0 array (Affymetrix).
Whole-Mount Staining and Immunohistochemistry
Immunostaining of embryos was performed as described previously (Li et al., 2003) . Briefly, embryos were fixed in 4% paraformaldehyde, bleached with 5% H 2 O 2 , blocked in 3% milk, incubated with primary antibodies and second antibody sequentially, and, finally, stained with the DAB kit (Vector labs). Antibodies used were anti-mouse CD31 (clone MEC13.3, Pharmingen), anti-SM a-actin (Clone 1A4, Sigma), anti-MMP10 (clone IVC5, Chemicon), anti-TIMP1 (polyclonal, Chemicon), and HRP-conjugated goat anti-rat IgG (Jackson ImmunoResearch). b-galactosidase staining of embryos and tissues was performed as described (Cheng et al., 1993) . After staining, samples were sectioned and counterstained with light eosin.
Electron Microscopy
Wild-type and HDAC7 mutant embryos were fixed overnight in 2% glutaraldehyde in 0.1 M cacodylate buffer at 4 C and then postfixed and dehydrated in an ethanol series. Samples were then embedded in Spurr resin (Ted Pella, Inc., Redding, CA), stained with uranyl acetate and lead citrate, and sectioned at 80 nm as described .
Cell Culture and Immunocytochemistry HUVEC cells were purchased from ATCC. HAEC cells were obtained from Clonetics. Both cell lines were cultured in EC growth medium (Clonetics/Cambrex). For immunostaining, cells were plated on gelatin-coated glass coverslips and were fixed and stained as described (McKinsey et al., 2000a) . HDAC7 antibody was purchased from Santa Cruz.
RNAi, Adenovirus Infection, and In Vitro Angiogenesis
SiRNA oligonucleotides for HDAC7 were purchased from Ambion and used at a concentration of 40 nM. SiRNA oligonucleotides for TIMP1 were purchased from Dharmacon and used a concentration of 70 nM. HUVECs were transfected with Liptofectamine Plus reagent (Invitrogen). Four days after transfection, cells were harvested either for RNA analysis or in vitro angiogenesis. Adenovirus encoding human MMP10 (Saunders, et al., 2005) was generously provided by Dr. George E. Davis (Texas A&M University). HUVECs were infected with either GFP or MMP10 adenovirus 2 days after RNAi transfection, and cells were harvested 2 days later. Matri-gel was purchased from Chemicon, and the assays were performed as instructed by the manufacturer. RT-PCR and in vitro angiogenesis were performed multiple times with comparable results. PCR primer sequences are available upon request. HDAC7-siRNA sequence is the following: TCACTG ACCTCGCCTTCAA.
Reporter Assays
The MMP10-luciferase construct contained a DNA fragment extending from À886 bp to +11 bp of the mouse MMP10 gene. The N-terminal flag-tagged HDAC7 and HDAC7 mutants were subcloned into pcDNA3.1 vector (Invitrogen). Amino acids 76-130 were deleted in the HDAC7-DMEF mutant. MEF2D and myc-tagged MEF2C were previously described (Phan et al., 2005) . COS cells in 24-well plates were transfected with 150 ng of reporter plasmids in the presence or absence of MEF2D or HDAC7. The reporter assays were performed as described (Chang et al., 2005) .
Gel Mobility Shift Assay
Gel mobility shift assays were performed as described (Chang et al., 2001) . COS cells were lysed 48 hr after transfection with a myc-tagged MEF2C expression plasmid or empty vector. The DNA probe was labeled with 32 P-dCTP using a Klenow fill-in method and purified using a G25 DNA purification column from Roche. The 20 ml binding reaction contained 1 mg of poly (dI-dC) (Sigma), 50,000 cpm of probe, and 2 ml of cell lysate. After incubation at room temperature for 15 min, the reactions were separated on a 5% PAGE gel containing 0.5 3 TBE.
Chromatin Immunoprecipitation Assay A ChIP kit was used for the assays according to manufacturer's instructions (Upstate Biotechnology). Acetyl-histone3 antibody was purchased from Upstate Biotechnology and MEF2 antibody was purchased from Santa Cruz. HDAC7 antibody and CBP antibodies were purchased from Abcam, and p300 antibody was purchased from Santa Cruz. Primer sequences are available upon request. Adenovirus encoding HDAC5 with alanine substitutions for serines 259 and 498 (S259/498A) was described previously (McKinsey et al., 2000a) .
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